PCM
VIVO

Prelude Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Prelude Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-59,592
Closed -$1.98M – 1664
2022
Q4 		$1.98M Sell
59,592
-16,436
-22% -$529K 0.1% 220
2022
Q3 		$2.4M Buy
+76,028
New +$2.46M 0.09% 189
2020
Q4 		– Sell
-318
Closed -$5K – 2185
2020
Q3 		$5K Buy
318
+200
+169% +$3.89K ﹤0.01% 1576
2020
Q2 		$3K Sell
118
-2,106
-95% -$30.5K ﹤0.01% 1805
2020
Q1 		$19K Buy
2,224
+2,201
+9,570% +$18.5K ﹤0.01% 1006
2019
Q4 		$0 Buy
+23
New +$216 ﹤0.01% 2353
2019
Q3 		– Sell
-11,187
Closed -$133K – 2185
2019
Q2 		$133K Buy
+11,187
New +$135K 0.01% 852
2019
Q1 		– Sell
-752
Closed -$13K – 2314
2018
Q4 		$13K Sell
752
-510
-40% -$8.7K ﹤0.01% 1327
2018
Q3 		$19K Buy
1,262
+45
+4% +$698 ﹤0.01% 1320
2018
Q2 		$19K Sell
1,217
-5,211
-81% -$77.7K ﹤0.01% 1367
2018
Q1 		$91K Buy
6,428
+3,536
+122% +$52.3K 0.01% 901
2017
Q4 		$40K Sell
2,892
-8,308
-74% -$122K ﹤0.01% 991
2017
Q3 		$160K Buy
11,200
+1,400
+14% +$20K 0.01% 717
2017
Q2 		$154K Sell
9,800
-15,692
-62% -$226K 0.01% 657
2017
Q1 		$352K Buy
+25,492
New +$356K 0.03% 388
2015
Q4 		– Sell
-1,800
Closed -$31K – 1753
2015
Q3 		$31K Buy
+1,800
New +$32.9K ﹤0.01% 1168
2015
Q2 		– Sell
-1,900
Closed -$36K – 2135
2015
Q1 		$36K Sell
1,900
-200
-10% -$3.7K 0.01% 1570
2014
Q4 		$35K Buy
+2,100
New +$36K 0.01% 1540
2013
Q4 		– Sell
-390
Closed -$9K – 1990
2013
Q3 		$9K Buy
+390
New +$9.11K ﹤0.01% 1319

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Prelude Capital Management's VIVO Position: Q1 2023 in Review

Prelude Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 59,592 shares — an estimated $1.98M sold.

Prelude Capital Management first reported a position in VIVO in Q3 2013 and held it in 19 quarters. The position peaked at $2.4M in Q3 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Prelude Capital Management reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Prelude Capital Management sold 59,592 Meridian Bioscience Inc shares in Q1 2023, an estimated $1.98M.
  • Prelude Capital Management first reported a position in Meridian Bioscience Inc in Q3 2013 and held it in 19 quarters.
  • Prelude Capital Management's Meridian Bioscience Inc position peaked at $2.4M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Prelude Capital Management's 13F filing for Q1 2023, filed 15 May 2023.